Telomelysin
Biologicalexperimental
Clinical trial activity
8 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02293850)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- obp-301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06340711 | Phase 2 | Apr 25, 2024 | Cornell University, Merck, Oncolys BioPharma Inc |
| NCT04685499 | Phase 2 | Dec 18, 2020 | Cornell University, Oncolys BioPharma Inc |
| NCT04391049 | Phase 1 | Jul 25, 2020 | National Cancer Institute (NCI), NRG Oncology |
| NCT03921021 | Phase 2 | May 9, 2019 | Cornell University, Oncolys BioPharma Inc |
| NCT03213054 | Phase 1 | Jul 7, 2017 | Oncolys BioPharma Inc |
| NCT03172819 | Phase 1 | Jul 1, 2017 | National Cancer Center Hospital East, Oncolys BioPharma Inc |
| NCT03190824 | Phase 2 | Dec 22, 2016 | INC Research, Oncolys BioPharma Inc, Syneos Health |
| NCT02293850 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2014 | Medigen Biotechnology Corporation, National Taiwan University, Oncolys BioPharma Inc |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oncolys BioPharma Inc | For profit | 7 | 2 | 2 | 2014 |
| Cornell University | Academic/Hospital | 3 | 3 | 1 | 2019 |
| INC Research | For profit | 1 | 1 | 1 | 2016 |
| Medigen Biotechnology Corporation | For profit | 1 | 0 | 1 | 2014 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| National Cancer Center Hospital East | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| NRG Oncology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Syneos Health | For profit | 1 | 0 | 1 | 2016 |
10 organizations
Page 1 / 1